| Literature DB >> 35366151 |
Xuan Pei1,2,3, Kai-Yue Li1,2, Yuan Shen1,2, Jin-Tao Li1,2, Ming-Zhu Lei1,2, Cai-Yun Fang1,2, Hao-Jie Lu1,2, Hui-Juan Yang2,3, Wenyu Wen1,4, Miao Yin1,2, Jia Qu5,6, Qun-Ying Lei7,8,9.
Abstract
Epithelial ovarian cancer (EOC) exhibits strong dependency on the tricarboxylic acid (TCA) cycle and oxidative phosphorylation to fuel anabolic process. Here, we show that malate dehydrogenase 2 (MDH2), a key enzyme of the TCA cycle, is palmitoylated at cysteine 138 (C138) residue, resulting in increased activity of MDH2. We next identify that ZDHHC18 acts as a palmitoyltransferase of MDH2. Glutamine deprivation enhances MDH2 palmitoylation by increasing the binding between ZDHHC18 and MDH2. MDH2 silencing represses mitochondrial respiration as well as ovarian cancer cell proliferation both in vitro and in vivo. Intriguingly, re-expression of wild-type MDH2, but not its palmitoylation-deficient C138S mutant, sustains mitochondrial respiration and restores the growth as well as clonogenic capability of ovarian cancer cells. Notably, MDH2 palmitoylation level is elevated in clinical cancer samples from patients with high-grade serous ovarian cancer. These observations suggest that MDH2 palmitoylation catalyzed by ZDHHC18 sustains mitochondrial respiration and promotes the malignancy of ovarian cancer, yielding possibilities of targeting ZDHHC18-mediated MDH2 palmitoylation in the treatment of EOC.Entities:
Keywords: EOC; MDH2; ZDHHC18; cysteine palmitoylation; glutamine
Mesh:
Substances:
Year: 2022 PMID: 35366151 DOI: 10.1007/s11427-021-2048-2
Source DB: PubMed Journal: Sci China Life Sci ISSN: 1674-7305 Impact factor: 10.372